The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis
Open accessAbstract
Patients with inflammatory bowel diseases are at increased risk for colorectal cancer, but the molecular mechanisms linking inflammation and cancer are not well defined. We earlier showed that carboxylated N-glycans expressed on receptor for advanced glycation end products (RAGE) and other glycoproteins mediate colitis through activation of nuclear factor kappa B (NF-kappaB). Because NF-kappaB signaling plays a critical role in the molecular pathogenesis of colitis-associated cancer (CAC), we reasoned that carboxylated glycans, RAGE and its ligands might promote CAC. Carboxylated glycans are expressed on a subpopulation of RAGE on colon cancer cells and mediate S100A8/A9 binding to RAGE. Colon tumor cells express binding sites for S100A8/A9 and binding leads to activation of NF-kappaB and tumor cell proliferation. Binding, downstream signaling and tumor cell proliferation are blocked by mAbGB3.1, an anti-carboxylate glycan antibody, and by anti-RAGE. In human colon tumor tissues and in a mouse model of CAC, we found that myeloid progenitors expressing S100A8 and S100A9 infiltrate regions of dysplasia and adenoma. mAbGB3.1 administration markedly reduces chronic inflammation and tumorigenesis in the mouse model of CAC and RAGE-deficient mice are resistant to the onset of CAC. These findings show that RAGE, carboxylated glycans and S100A8/A9 play essential roles in tumor-stromal interactions, leading to inflammation-associated colon carcinogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NF-κB: linking inflammation and immunity to cancer development and progression
Karin, M., & Greten, F. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1703 · Cited by 3,085
Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis
Condeelis, J., & Pollard, J. W. (2006) · Cell · doi:10.1016/j.cell.2006.01.007 · Cited by 2,695
IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer
Greten, F. R., Eckmann, L., Greten, T. F., Park, J. M., Li, Z.-W., Egan, L. J., Kagnoff, M. F., & Karin, M. (2004) · Cell · doi:10.1016/j.cell.2004.07.013 · Cited by 2,433
RAGE Mediates a Novel Proinflammatory Axis
Hofmann, M. A., Drury, S., Fu, C., Qu, W., Taguchi, A., Lu, Y., Avila, C., Kambham, N., Bierhaus, A., Nawroth, P., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80801-6 · Cited by 1,864
Self-citationDonato, R. (2001) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(01)00046-2 · Cited by 1,580
Vogl, T., Tenbrock, K., Ludwig, S., Leukert, N., Ehrhardt, C., van Zoelen, M. A. D., Nacken, W., Foell, D., van der Poll, T., Sorg, C., et al. (2007) · Nature Medicine · doi:10.1038/nm1638 · Cited by 1,418
Self-citationUnderstanding RAGE, the receptor for advanced glycation end products
Bierhaus, A., Humpert, P. M., Morcos, M., Wendt, T., Chavakis, T., Arnold, B., Stern, D. M., & Nawroth, P. P. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-005-0688-7 · Cited by 1,297
Self-citationItzkowitz, S. H., & Yio, X. (2004) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00079.2004 · Cited by 1,274
The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses
Schmidt, A. M., Yan, S. D., Yan, S. F., & Stern, D. M. (2001) · Journal of Clinical Investigation · doi:10.1172/jci14002 · Cited by 1,253
Dieleman, L. A., Palmen, M. J. H. J., Akol, H., Bloemena, E., PEña, A. S., Meuwissen, S. G. M., & Van Rees, E. P. (2001) · Clinical and Experimental Immunology · doi:10.1046/j.1365-2249.1998.00728.x · Cited by 1,165
Cited by
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Terzić, J., Grivennikov, S., Karin, E., & Karin, M. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.01.058 · Cited by 1,974
Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Ostrand-Rosenberg, S., & Sinha, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802740 · Cited by 1,736
Self-citationDonato, R., R. Cannon, B., Sorci, G., Riuzzi, F., Hsu, K., J. Weber, D., & L. Geczy, C. (2013) · Current Molecular Medicine · doi:10.2174/156652413804486214 · Cited by 1,316
Ehrchen, J. M., Sunderkötter, C., Foell, D., Vogl, T., & Roth, J. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.1008647 · Cited by 846
Self-citationProinflammatory S100 Proteins Regulate the Accumulation of Myeloid-Derived Suppressor Cells
Sinha, P., Okoro, C., Foell, D., Freeze, H. H., Ostrand-Rosenberg, S., & Srikrishna, G. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.7.4666 · Cited by 725
Self-citationSparvero, L. J., Asafu-Adjei, D., Kang, R., Tang, D., Amin, N., Im, J., Rutledge, R., Lin, B., Amoscato, A. A., Zeh, H. J., et al. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-17 · Cited by 622
Erin, N., Grahovac, J., Brozovic, A., & Efferth, T. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100715 · Cited by 527
Alarmins: awaiting a clinical response
Chan, J. K., Roth, J., Oppenheim, J. J., Tracey, K. J., Vogl, T., Feldmann, M., Horwood, N., & Nanchahal, J. (2012) · Journal of Clinical Investigation · doi:10.1172/jci62423 · Cited by 511
Self-citationTargeting RAGE Signaling in Inflammatory Disease
Hudson, B. I., & Lippman, M. E. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-041316-085215 · Cited by 502
Binding of S100 proteins to RAGE: An update
Leclerc, E., Fritz, G., Vetter, S. W., & Heizmann, C. W. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2008.11.016 · Cited by 489
Damage-associated molecular patterns in cancer: a double-edged sword
Hernandez, C., Huebener, P., & Schwabe, R. F. (2016) · Oncogene · doi:10.1038/onc.2016.104 · Cited by 480
HMGB1, IL-1α, IL-33 and S100 proteins: dual-function alarmins
Bertheloot, D., & Latz, E. (2017) · Cellular & Molecular Immunology · doi:10.1038/cmi.2016.34 · Cited by 455
S100 Proteins As an Important Regulator of Macrophage Inflammation
Xia, C., Braunstein, Z., Toomey, A. C., Zhong, J., & Rao, X. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01908 · Cited by 424
Innate immune mechanisms of colitis and colitis-associated colorectal cancer
Saleh, M., & Trinchieri, G. (2011) · Nature Reviews Immunology · doi:10.1038/nri2891 · Cited by 403
Poschke, I., Mougiakakos, D., Hansson, J., Masucci, G. V., & Kiessling, R. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3767 · Cited by 382
S100A8/A9 activate key genes and pathways in colon tumor progression
Ichikawa, M., Williams, R., Wang, L., Vogl, T., & Srikrishna, G. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0394 · Cited by 346
Self-citationInflammation-associated S100 proteins: new mechanisms that regulate function
Goyette, J., & Geczy, C. L. (2011) · Amino Acids · doi:10.1007/s00726-010-0528-0 · Cited by 345
Bierhaus, A., & Nawroth, P. P. (2009) · Diabetologia · doi:10.1007/s00125-009-1458-9 · Cited by 314
Self-citationMyeloid derived suppressor cells – a new therapeutic target in the treatment of cancer
Wesolowski, R., Markowitz, J., & Carson, W. E. (2013) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-1-10 · Cited by 291
Kang, R., Tang, D., Schapiro, N. E., Livesey, K. M., Farkas, A., Loughran, P., Bierhaus, A., Lotze, M. T., & Zeh, H. J. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.149 · Cited by 283
Self-citationSrikrishna, G., & Freeze, H. H. (2009) · Neoplasia · doi:10.1593/neo.09284 · Cited by 275
Self-citationSchiopu, A., & Cotoi, O. S. (2013) · Mediators of Inflammation · doi:10.1155/2013/828354 · Cited by 270
Emerging avenues linking inflammation and cancer
Kundu, J. K., & Surh, Y.-J. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.02.035 · Cited by 264
S100A8 and S100A9: New Insights into Their Roles in Malignancy
Srikrishna, G. (2012) · Journal of Innate Immunity · doi:10.1159/000330095 · Cited by 258
Self-citationRAGE and TLRs: Relatives, friends or neighbours?
Ibrahim, Z. A., Armour, C. L., Phipps, S., & Sukkar, M. B. (2013) · Molecular Immunology · doi:10.1016/j.molimm.2013.07.008 · Cited by 257
Nutritional immunity: S100 proteins at the host–pathogen interface
Zackular, J. P., Chazin, W. J., & Skaar, E. P. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.645085 · Cited by 235
Proinflammatory effects of S100A8/A9 via TLR4 and RAGE signaling pathways in BV-2 microglial cells
Ma, L., Sun, P., Zhang, J.-C., Zhang, Q., & Yao, S.-L. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.2987 · Cited by 196
Nedić, O., Rattan, S. I. S., Grune, T., & Trougakos, I. P. (2013) · Free Radical Research · doi:10.3109/10715762.2013.806798 · Cited by 162
RAGE-Mediated Inflammation, Type 2 Diabetes, and Diabetic Vascular Complication
Yamamoto, Y., & Yamamoto, H. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00105 · Cited by 99
Pusterla, T., Nèmeth, J., Stein, I., Wiechert, L., Knigin, D., Marhenke, S., Longerich, T., Kumar, V., Arnold, B., Vogel, A., et al. (2013) · Hepatology · doi:10.1002/hep.26395 · Cited by 97
Self-citationManolakis, A. C., Kapsoritakis, A. N., Tiaka, E. K., & Potamianos, S. P. (2011) · Digestive Diseases and Sciences · doi:10.1007/s10620-010-1494-9 · Cited by 96
Metadata
- Authors
- Turovskaya, O., Foell, D., Sinha, P., Vogl, T., Newlin, R., Nayak, J., Nguyen, M., Olsson, A., Nawroth, P. P., Bierhaus, A., Varki, N., Kronenberg, M., Freeze, H. H., & Srikrishna, G.
- Venue
- Carcinogenesis
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-08-09
- Volume
- 29
- Issue
- 10
- Pages
- 2035-2043
- ISSN
- 0143-3334 (ISSN-L)
- 1460-2180
- OpenAlex
- W2111463022
- Cited by
- 295
- References
- 49
- FWCI
- 11.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.